

spectrum antibiotics and only if there is no improvement are such patients considered for antituberculous therapy.

Highly active antiretroviral therapy adherence

It was assessed using both tablet counting and self-reporting methods. In the tablet counting method, pharmacy medication records for patients were matched by the pharmacist against the not-yet-used medicines brought to the pharmacy by the patients as a routine for refill of prescriptions, and the number of doses that ought to have been taken that were missed were recorded.^[25] In the self-reporting method, patients were interviewed about their adherence over the previous day, previous week, and previous month successively.^[26] If there was discrepancy between the two methods, the tablet counting method was used.

Adherence was defined as taking 95% of prescribed doses which corresponded to missing no >1 dose in a 10-day period (in 2 times a day dosing regimen), or one dose per month (in a once daily regimen).^[25] Patients were therefore said to have HAART non-adherence if they missed >5% of their doses.^[25,26] HAART adherence was reported as a dichotomous variable (i.e., yes or no).

Social class

It was assessed using the paternal occupation/income and the maternal educational attainment as recommended for Nigeria.^[27] This method stratifies social class into five classes I to V. Class I represent the upper cadre, classes II and III the middle cadre, whereas classes IV and V are the lower cadre. Paternal occupation had a cumulative score of 3, whereas maternal educational attainment had a cumulative score of 2. The total score from both parameters placed each participant in the respective classes. This classification system is judged relevant in developing countries such as Nigeria where the mother's education often influences healthcare knowledge and health seeking behavior in the family irrespective of household income.

Ethical considerations

Ethical approval was obtained from the Ethics Committee of FMCO. Written informed consent was obtained from each patient before enrollment and confidentiality were ensured by every member of the research team. All patients newly diagnosed with TB were referred for appropriate treatment.

Data management and analysis

Data entry and analysis were carried out using the Epi Info version 3.5.1 statistical software (CDC, Atlanta, Georgia, 2008). Completed questionnaires were coded by numbers and double entered in the Epi Info software. Cross-checking and data cleaning were done. Data were presented as proportions for categorical variables. Quantitative variables were presented as mean (standard deviation) if they were normally distributed while non-normally distributed

quantitative data were presented as median (interquartile range). The Student's *t*-test was used to compare mean values of normally distributed quantitative variables, whereas non-normally distributed variables were compared using the Kruskal–Wallis test.

Bivariate comparisons utilized the Chi-square test as appropriate. Quantitative variables were dichotomized using cutoff points that had clinical relevance and that were as close as possible to the mean or median values in the entire population. For body mass index (BMI), the clinical relevance of 18.5kg/m² as a cutoff point was considered more important than the mean value since TB usually presents with weight loss. A cutoff point of 200cells/μl was used for current CD4 count rather than the median value to better assess the impact of severe immunosuppression post-HAART.

Logistic regression model was used to determine the factors independently associated with prevalent TB using parameters that had a *P* < 0.1 on bivariate analysis. Statistical significance was set at *P* < 0.05.

Results

Characteristics of the study participants

Of the 354 patients enrolled, 15 had several missing data, so we included only 339 patients with complete data for the analysis [Figure 1]. In the final study population, 65.8% (222/339) were women. The mean age of the entire population was 41.1 (10.0) years. Urban dwellers constituted 56.3% (191/339) of the participants, and 50.4% (171/339) belonged to the lower social class. About one-fifth had a positive history of current alcohol use and 7.1% (24/339) ever smoked. Previous history of TB was documented in 23.6% (73/339) of patients. The most frequent WHO clinical stage at the time of HIV diagnosis was stage I comprising 41.0% (139/339) of patients followed by stage II comprising 31.3% (106/339) while the remaining 27.7% (94/339) presented at stages III or IV. About 49.6% (168/339) of the patients had baseline CD4 count <200 cells/μl, whereas the median current (post-HAART) CD4 count was 357 (211–496) cells/μl. The median durations of HIV diagnosis and HAART were 3.2 (2.0–5.0) years and 35.0 (20.0–50.0) months, respectively. HAART non-adherence was documented in 22.4% (76/339) of participants.

Table 1 shows the characteristics of the study participants according to TB status. There were statistically significant differences between the two groups in social class and HIV/HAART/other clinical parameters with the exception of duration of HIV diagnosis.

Prevalence and types of tuberculosis

In the entire study population, 12.7% (43/339) had a positive screening based on the TB screening algorithm used. Active

TB was diagnosed in 7.7% (26/339) of patients. The 26 patients included 9 patients whose TB were diagnosed after initiation of HAART and were still on anti-TB drugs at the time of the study and 17 who were newly diagnosed during the study. Of these TB cases, 42.3% (11/26) had pulmonary TB, 34.6% (9/26) had disseminated TB, whereas the remaining patients had only extrapulmonary disease including tuberculous pleural effusion in 11.5% (3/26) of patients, TB lymphadenitis in 7.7% (2/26), and abdominal TB in 3.8% (1/26). In all, 20 patients had evidence of pulmonary involvement out of whom only 45% (9/20) had positive sputum smear.

Bivariate analysis for factors associated with prevalent tuberculosis

Bivariate analysis of factors associated with prevalent TB is presented in Table 2. All variables were dichotomized. Patients with TB were significantly more likely to belong to lower social class ($P = 0.02$). There was no statistically significant relationship between prevalent TB and age ($P = 0.77$), gender ($P = 0.08$), location of residence ($P = 0.50$), current alcohol use ($P = 0.81$), or having ever smoked ($P = 0.09$).

A number of HIV severity and HAART-related parameters showed significant associations with prevalent TB including WHO clinical stage III/IV ($P < 0.001$) and HAART non-adherence ($P < 0.001$). Patients with TB were significantly more likely to have baseline CD4 count < 200 cells/ μ l ($P < 0.001$) and current CD4 count < 200 cells/ μ l ($P < 0.001$). Neither duration of HIV diagnosis < 3 years ($P = 0.08$) nor HAART duration < 35 months ($P = 0.05$) had statistically significant association with prevalent TB.

Compared with patients without TB, those with TB had a higher proportion of individuals with past history of TB, BMI < 18.5 kg/ m^2 , baseline hemoglobin < 10 g/dl, and current hemoglobin < 10 g/dl (all $P < 0.001$).

Multivariate analysis for factors associated with prevalent tuberculosis

To identify factors independently associated with prevalent TB, we created a logistic regression model using factors that had $P < 0.1$ on bivariate analysis as shown in Table 3. The factors that were independently associated with prevalent TB were lower social class ($P = 0.04$), baseline CD4 count < 200 cells/ μ l ($P = 0.02$), HAART non-adherence ($P < 0.001$), previous TB ($P < 0.01$), and current hemoglobin < 10 g/dl ($P = 0.04$).

Discussion

We found a prevalence of active TB of 7.7% among HIV-infected patients who had received HAART for an average of 35 months in a high TB burden nation. Prevalent TB was associated with lower social class, severe immunosuppression before HAART initiation, HAART non-adherence, previous history of TB, and current hemoglobin < 10 g/dl.

Table 1: Characteristics of the study participants according to tuberculosis status

Characteristics	TB (n=26)	No TB (n=313)	P
Demographics			
Male, n (%)	13 (50.0)	103 (32.9)	0.08
Age (years) [†]	38.0 (6.6)	41.4 (10.2)	0.09
Rural residence, n (%)	13 (50.0)	135 (43.1)	0.50
Lower social class (4 and 5), n (%)	19 (73.1)	152 (48.6)	0.02
Health behavior, n (%)			
Ever smoked	4 (15.4)	20 (6.4)	0.09
Current alcohol use	6 (23.1)	66 (21.1)	0.08
HIV severity and HAART			
HIV duration (years) [#]	2.7 (1.0-6.0)	3.3 (2.0-5.0)	0.61
Baseline WHO clinical stage III/IV, n (%)	18 (69.2)	76 (24.3)	< 0.001
HAART duration (months) [#]	15.5 (6.0-36.0)	36.0 (22.0-52.0)	0.02
HAART non-adherence, n (%)	24 (92.3)	52 (16.6)	< 0.001
Baseline CD4 count (cells/ μ l) [#]	90 (53-165)	201 (119-267)	< 0.001
Current CD4 count, (cells/ μ l) [#]	165 (85-216)	371 (233-523)	< 0.001
Other clinical parameters			
Previous TB, n (%)	15 (57.7)	58 (20.5)	< 0.001
BMI (kg/ m^2) [†]	20.1 (4.0)	24.8 (5.3)	< 0.001
Baseline haemoglobin [†]	9.4 (2.2)	11.4 (1.9)	< 0.001
Current haemoglobin [†]	9.6 (2.2)	11.8 (1.5)	< 0.001

[†]Variables are expressed as means (SD), [#]Variables are expressed as median (IQR).
 BMI: Body mass index, TB: Tuberculosis, HAART: Highly active antiretroviral therapy,
 IQR: Interquartile range, SD: Standard deviation

Table 2: Factors associated with prevalent tuberculosis in HIV-infected patients on highly active antiretroviral therapy (bivariate analysis)

Variable	OR (95% CI)	P
Demographic/health behavior factors		
Age (≤ 40 vs. > 40 years)	1.1 (0.5-2.6)	0.77
Gender (male vs. female)	2.0 (0.9-4.6)	0.08
Social class (4 and 5 vs. 1-3)	2.9 (1.2-7.5)	0.02
Residence (Rural vs. Urban)	0.7 (0.3-1.7)	0.50
Ever smoked versus never smoked	2.6 (0.7-8.1)	0.09
Current alcohol use (yes vs. no)	1.1 (0.4-2.8)	0.81
HIV severity and treatment factors		
Baseline WHO clinical stage (III/IV vs. I/II)	7.0 (3.0-17.6)	< 0.001
HIV duration (< 3 vs. ≥ 3 years)	2.0 (0.89-4.5)	0.08
HAART duration (< 35 vs. ≥ 35 months)	0.4 (0.2-1.0)	0.05
HAART nonadherence (yes vs. no)	59.2 (15.7-381.9)	< 0.001
Baseline CD4 count (< 200 vs. ≥ 200 cells/ μ l)	29.5 (5.4-620.0)	< 0.001
Current CD4 count (< 200 vs. ≥ 200 cells/ μ l)	10.0 (4.2-25.5)	< 0.001
Other clinical factors		
BMI (< 18.5 vs. ≥ 18.5 kg/ m^2)	6.6 (2.7-15.8)	< 0.001
Baseline hemoglobin (< 10 vs. ≥ 10 g/dl)	8.1 (3.4-19.8)	< 0.001
Current hemoglobin (< 10 vs. ≥ 10 g/dl)	12.4 (5.1-30.5)	< 0.001
Previous TB (yes vs. no)	5.3 (2.3-12.4)	< 0.001

BMI: Body mass index, TB: Tuberculosis, HAART: Highly active antiretroviral therapy,
 OR: Odds ratio, WHO: World Health Organization, CI: Confidence interval

Table 3: Factors associated with prevalent tuberculosis in HIV-infected patients on highly active antiretroviral therapy (multivariate analysis)

Variable	aOR (95% CI)	P
Gender (male vs. female)	1.5 (0.2-10.0)	0.64
Social class (4 and 5 vs. 1-3)	31.7 (1.1-1417.3)	0.04
Ever smoked versus never smoked	1.9 (0.1-52.2)	0.46
Baseline WHO clinical stage (III/IV vs. I/II)	0.2 (0.0-1.8)	0.16
HIV duration (<3 vs. ≥3 years)	0.1 (0.0-1.6)	0.11
HAART duration (<35 vs. ≥35 months)	6.7 (0.5-82.3)	0.14
HAART nonadherence (yes vs. no)	125.5 (9.6-1636.3)	<0.001
Baseline CD4 count (<200 vs. ≥200 cells/μl)	31.0 (1.6-590.6)	0.02
Current CD4 count (<200 vs. ≥200 cells/μl)	2.1 (0.3-16.4)	0.46
BMI (<18.5 vs. ≥18.5 kg/m ²)	2.6 (0.3-19.8)	0.36
Baseline hemoglobin (<10 vs. ≥10 g/dl)	4.5 (0.6-31.7)	0.13
Current hemoglobin (<10 vs. ≥10 g/dl)	10.3 (1.1-99.2)	0.04
Previous TB (yes vs. no)	13.8 (2.0-94.1)	<0.01

BMI: Body mass index, TB: Tuberculosis, HAART: Highly active antiretroviral therapy, OR: Odds ratio, aOR: Adjusted odds ratio, WHO: World Health Organization, CI: Confidence interval

The findings of this study are considered important because identifying the high-risk groups for active TB as shown in this study may lead to a higher index of suspicion, closer follow-up, more intensive screening for TB, and earlier TB diagnosis with possibly improved outcome. In addition, addressing the factors associated with TB such as HAART non-adherence and lower social class may prove to be key strategies for improved prevention and control of active TB in patients receiving HAART at least in the context of developing countries with high TB burden. The issue of HAART adherence as a means of TB control in PLHIV deserves to be emphasized bearing in mind that HAART has generally improved the quality of life of PLHIV, and undeniably changed the epidemiology of TB for the better in countries with high prevalence of this co-infection.

The prevalence of TB documented in HIV patients on HAART in this study is comparable with findings in Brazil (6.8%-all forms of TB),^[28] Tanzania (8.5%-pulmonary TB),^[29] and Ethiopia (10.1%-all forms of TB).^[30] The study in Brazil was a retrospective analysis of 599 HIV-positive patients out of whom 59% were on HAART. TB diagnosis was based on sputum smear positivity or mycobacterial culture or physician-diagnosed cases. The majority (73%) had pulmonary TB.^[28] The study in Tanzania was cross-sectional and involved 233 patients of whom 74% were women. Children were included in the study though the mean age was 37 (10) years. About 15% had a past history of TB. TB was defined as cases positive for AFB by smear microscopy and/or culture.^[29] In Ethiopia, a cross-sectional study of 385 HIV-positive patients was conducted with 91% on HAART, 64% women and mean age of 35.9 (9.2) years. About 27% of their patients had CD4 count <200cell/μl. The case definition of TB was not clearly stated.^[30]

Some other high TB burden settings have reported lower rates of 3–5% (all forms of TB) in ART-experienced populations.^[11,31] Although the case definitions of TB in those studies were comparable with that of our study, a possible reason for the difference in the reported rates of TB is that those studies involved much larger samples of 28,323 and 2514 subjects in the works of Nicholas *et al.* And Peck *et al.*, respectively.^[11,31]

On the other hand, some other studies have reported much higher rates of prevalent TB in patients receiving HAART: 17–27% in other settings in India that investigated only pulmonary TB^[32,33] and 19.8% in Benin City, Nigeria.^[34] There are some explanations for the disparity between these studies and ours. In the work of Giri *et al.*,^[32] half of their participants were men, and over 70% had CD4 count <250cells/μl. The reason for the higher rate of prevalent TB in Benin City, Nigeria may be because only 70% of their participants were on HAART and understandably the remaining 30% who were HAART naïve had higher TB risk.

Generally, the availability of mycobacterial culture is another reason for variation in rates of diagnosed TB. For example, the prevalence documented for pulmonary TB by Ngowi,^[29] in a setting in Tanzania where mycobacterial culture was employed in diagnosis in some patients was 3 times higher than the prevalence of all forms of TB documented by Peck *et al.*^[31] in another Tanzanian setting where mycobacterial culture was not available.

The WHO estimated that only 3% of HIV-infected individuals developed TB in 2010 in Nigeria^[14] although this data did not specify antiretroviral treatment status. Hospital-based studies have shown that the prevalence of active TB in predominantly HAART naïve HIV-infected patients in Nigeria was 30–40% before antiretroviral drugs became readily available^[35,36] and 6–14% in the post-HAART era.^[37-39] Our finding on the prevalence of active TB among patients on HAART is therefore within the range described in the post-HAART era in other studies in Nigeria.

While there is evidence that TB can occur in HIV-infected patients at any level of CD4 count,^[9] low CD4 count before HAART initiation has consistently been reported to be a risk factor for TB in patients on HAART.^[7,8,10,37,38] According to Girardi *et al.*,^[7] baseline CD4 count was associated with the occurrence of TB in Europe and North America from 6 months after initiation of HAART even after controlling for the 6-month CD4 count which was also predictive of TB. In South Africa, the risk of TB was independently associated with CD4 count <100cells/μl. In an evaluation of the relationship between TB and CD4 count in HIV-infected patients in another study in Nigeria, patients with CD4 count ≤200cells/μl were significantly more likely to have TB compared to those with values >200cells/μl.^[37]

Similar to our finding, past history of TB has been reported to be a risk factor for active TB among patients on HAART in various studies in sub-Saharan Africa.^[9,11,13,40] In a prospective cohort study in Coted'Ivoire, the risk of TB after HAART initiation was 2 times higher in patients with a past history of TB compared to those who had no past history of TB.^[40] According to Komati *et al.*,^[13] a history of TB at baseline was associated with subsequent TB and death during HAART in South Africa. Contrary to these reports, Lawn *et al.*^[8] found that previous TB was not associated with subsequent TB in patients on HAART in another South African cohort. In that study, only 14% of the population had a past history of TB compared to about 24% in our study, so it is possible this contributed to the disparity.

While we found that low social class was independently associated with TB, Lawn *et al.*^[8] reported that socioeconomic status was not a risk factor for TB in their population despite the fact that the proportion of individuals with low social class was similar in the two studies (51% in South Africa and 50.4% in our study). In line with our findings, HAART adherence <95% was identified as a strong predictor of TB in Mozambique.^[41] Anemia has also been associated with TB in a number of studies.^[10,11,13,30]

We observed that the significant association between either post-HAART CD4 count or WHO clinical stage III/IV and active TB seen on bivariate analysis was lost after controlling for confounders. Advanced WHO clinical stage at the time of HIV diagnosis^[8,13,38,42-44] and low CD4 count post-HAART^[7,10,12,32] have been shown in several studies to predict active TB in patients receiving HAART. Age, gender, and low BMI were not predictors of active TB in our study. The observation by Lawn *et al.*^[8] that gender had no significant association with TB in South Africa despite a male predominance in their population agrees with our finding. Some other studies have reported younger age,^[8,34] male gender,^[11,20,39,42] and low BMI^[10,11,13,29] to be significantly associated with TB disease in patients on HAART. It is possible that our study was underpowered to detect some of these associations. Another reason for the lack of association between WHO clinical stage and TB in our study may be the relatively low proportion of patients with advanced WHO clinical stage (27.7%).

It is also important to note that high HIV viral load both at baseline or during HAART has been strongly associated with active TB both in high and low TB burden countries.^[7,10,13] We were unable to assess for the association between HIV viral load and prevalent TB due to lack of facilities for viral load quantification in our center at the time of this study which unfortunately is the case in most resource-limited settings.

Our study had a number of strengths. Selection bias was reasonably minimized by the use of a simple random sampling technique. The inclusion of only patients who had received

HAART long enough to attain some immunological recovery and virological suppression mean that we did not recruit a group of HIV-infected patients who had unduly high risk of TB or unmasking TB immune reconstitution inflammatory syndrome. The TB diagnostic criteria, we adopted also minimized the chances of TB overdiagnosis.

Nevertheless, our observation should be interpreted in the light of our study limitations. Considering that the sample size was estimated based on a larger study on OIs, our study could have been underpowered to detect associations between prevalent TB and some other variables such as WHO clinical stage and post-HAART CD4count. We did not have facilities for sputum mycobacterial culture or GeneXpert at the time of this study either of which would have further improved the sensitivity of our TB diagnosis considering that our patients were HIV-infected and may present with atypical clinical features, unremarkable chest radiograph, and smear negative sputum despite having TB. Therefore, the actual prevalence of active TB in our HAART population may be higher than we found. Availability of mycobacterial culture for TB diagnosis remains a challenge in resource-limited settings. In fact, mycobacterial culture is highly prioritized for TB diagnosis in Nigeria and is not yet indicated for routine diagnosis irrespective of HIV status even in the 2014 revised National guideline.^[23] The fact that we did not use more objective criteria such as Cage criteria for alcohol use and number of pack-years for cigarette smoking are also considered limitations in this study. This is worth mentioning considering that both chronic alcohol use and cigarette smoking are recognized risk factors for pulmonary infections.

Conclusion

This study has shown that prevalent TB remains an important public health problem among HIV-infected patients receiving HAART in high TB burden nations. Lower social class, previous TB, HAART non-adherence, severe immunosuppression before HAART initiation, and anemia post-HAART were factors independently associated with prevalent TB. We recommend that TB and HIV policy makers as well as clinicians should consider these findings to review TB management guidelines to raise the index of suspicion for TB diagnosis in these high-risk groups. Addressing key issues such as HAART non-adherence and poor living conditions in PLHIV in resource-limited settings is highly recommended as part of TB prevention strategy. The observation that baseline CD4 count below 200cells/ μ l was associated with prevalent TB underscores the importance of commencement of ART at higher CD4 count in line with current WHO recommendation.^[45] Finally, the likelihood that the prevalence of active TB in our population may actually be higher than we found justifies a call for policy makers and relevant authorities in resource-limited settings such as Nigeria to make mycobacterial culture and molecular-based techniques such as GeneXpert readily available for TB diagnosis, especially in PLHIV.

Acknowledgment

This study was part of the thesis submitted to the School of Public Health, University of Western Cape, South Africa for the award of Master of Public health to MOI. Support for laboratory investigations was provided by the heart-to-heart clinic of FMCO.

We thank our patients for participating in this study. The clinical and administrative staff of the heart-to-heart clinic of FMCO is deeply appreciated for their assistance during data collection. We also wish to thank the resident doctors and house officers that assisted with patient recruitment. Cecy Patino-Suton of the American Thoracic Society Methods in Epidemiologic, Clinical, and Operations Research (ATS-MECOR) Global course is deeply appreciated for her input.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

- Ogoina D, Obiako RO, Muktar HM, Adeiza M, Babadoko A, Hassan A, *et al.* Morbidity and mortality patterns of hospitalised adult HIV/AIDS patients in the era of highly active antiretroviral therapy: A 4-year retrospective review from Zaria, Northern Nigeria. *AIDS Res Treat* 2012;2012:940580.
- Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: Opportunities, challenges, and change in the era of antiretroviral treatment. *Lancet* 2006;367:926-37.
- WHO. Global Tuberculosis Report (2013). Geneva, Switzerland: WHO; 2013.
- Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. *Clin Infect Dis* 2002;34:543-6.
- Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker SA, *et al.* Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. *Int J Epidemiol* 2002;31:951-8.
- Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: A cohort study. *Lancet* 2002;359:2059-64.
- Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, *et al.* Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. *Clin Infect Dis* 2005;41:1772-82.
- Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: Long term incidence and risk factors in a South African cohort. *AIDS* 2005;19:2109-16.
- Bwana V, Tenu F, Magesa SM, Mfinanga SG. Smear positive pulmonary tuberculosis among HIV patients receiving highly active antiretroviral therapy in Dar es Salaam, Tanzania. *Tanzan J Health Res* 2011;13:14-20.
- Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: Incidence, risk factors, and prevention strategies. *J Acquir Immune Defic Syndr* 2011;56:349-55.
- Nicholas S, Sabapathy K, Ferreyra C, Varaine F, Pujades-Rodríguez M; AIDS Working Group of Médecins Sans Frontières. Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs. *J Acquir Immune Defic Syndr* 2011;57:311-8.
- Akanbi MO, Achenbach CJ, Feinglass J, Taiwo B, Onu A, Pho MT, *et al.* Tuberculosis after one year of combination antiretroviral therapy in Nigeria: A retrospective cohort study. *AIDS Res Hum Retroviruses* 2013;29:931-7.
- Komati S, Shaw PA, Stubbs N, Mathibedi MJ, Malan L, Sangweni P, *et al.* Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa. *AIDS* 2010;24:1849-55.
- Federal Ministry of Health. National HIV/Syphilis Seroprevalence Sentinel Survey Among Pregnant Women Attending Antenatal Clinics in Nigeria. Department of Public Health National AIDS/STI Control Programme, 2010. Abuja, Nigeria; 2010.
- United States Embassy in Nigeria. Nigeria Tuberculosis Fact Sheet, 2012. Abuja, Nigeria; 2012. Available from: <http://www.photos.state.gov/libraries/nigeria/487468/pdfs/JanuaryTuberculosisFactSheet.pdf>. [Last accessed on 2016 Apr 02].
- Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, *et al.* Implementation of isoniazid preventive therapy for people living with HIV worldwide: Barriers and solutions. *AIDS* 2010;24 Suppl 5:S57-65.
- National Population Commission of Nigeria. Population Census of the Federal Republic of Nigeria, 2006. Abuja, Nigeria: National Population Commission of Nigeria; 2006.
- Iroezindu MO, Ofondu EO, Hausler H, van Wyk B. Prevalence and risk factors for opportunistic infections in HIV patients receiving antiretroviral therapy in a resource-limited setting in Nigeria. *J AIDS Clin Res* 2013;S3:002. doi: 10.4172/2155-6113.S3-002.
- Mzileni MO, Longo-Mbenza B, Chepche TJ. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital. *Pol Arch Med Wewn* 2008;118:548-54.
- Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, *et al.* An algorithm for tuberculosis screening and diagnosis in people with HIV. *N Engl J Med* 2010;362:707-16.
- Sharma SK, Kadhiravan T, Banga A, Goyal T, Bhatia I, Saha PK. Spectrum of clinical disease in a series of 135 hospitalised HIV-infected patients from North India. *BMC Infect Dis* 2004;4:52.
- Ghate M, Deshpande S, Tripathy S, Nene M, Gedam P, Godbole S, *et al.* Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: Analysis by stages of immunosuppression represented by CD4 counts. *Int J Infect Dis* 2009;13:e1-8.
- Federal Ministry of Health. National tuberculosis, leprosy

- and buruli ulcer management and control guidelines. 6th ed. Abuja, Nigeria: Federal Ministry of Health; 2014.
24. World Health Organization. Treatment of tuberculosis: Guidelines for national programs. Geneva, Switzerland: World Health Organization; 2003.
 25. Erah PO, Arute JE. Adherence of HIV/AIDS patients to antiretroviral therapy in a tertiary health facility in Benin city. *Afr J Pharm Pharmacol* 2008;2:145-52.
 26. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, *et al.* Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. *J Acquir Immune Defic Syndr* 2003;34:281-8.
 27. Olusanya O, Okpere EE, Ezimokhai M. The importance of socioeconomic class in voluntary fertility in developing countries. *West Afr Med J* 1985;4:205-7.
 28. Casseb J, Fonseca LA, Medeiros LA, Gonsalez CR, Lagonegro ER, Veiga AP, *et al.* Tuberculosis among HIV-1-infected subjects in a tertiary out-patient service in São Paulo city, Brazil. *Rev Inst Med Trop Sao Paulo* 2012;54:257-9.
 29. Ngowi BJ, Mfinanga SG, Bruun JN, Morkve O. Pulmonary tuberculosis among people living with HIV/AIDS attending care and treatment in rural Northern Tanzania. *BMC Public Health* 2008;8:341.
 30. Belay A, Alamrew Z, Berie Y, Tegegne B, Tiruneh G, Felek A. Magnitude and correlates of tuberculosis among HIV patients at Felege Hiwot Referral Hospital, Bahir Dar city, Northwest Ethiopia. *Clin Med Res* 2013;2:77-83.
 31. Peck RN, Luhanga A, Kalluvya S, Todd J, Lugoba S, Fitzgerald DW, *et al.* Predictors of tuberculosis in first 6 months after initiation of antiretroviral therapy: A case-control study. *Int J Tuberc Lung Dis* 2012;16:1047-51.
 32. Giri PA, Deshpande JD, Phalke DB. Prevalence of pulmonary tuberculosis among HIV positive patients attending antiretroviral therapy clinic. *N Am J Med Sci* 2013;5:367-70.
 33. Padyana M, Bhat RV, Dinesha M, Nawaz A. HIV-tuberculosis: A study of chest X-ray patterns in relation to CD4 count. *N Am J Med Sci* 2012;4:221-5.
 34. Okoh A, Omuemu V. Prevalence of HIV/AIDS and tuberculosis co-infection among patients in Benin city, Nigeria. Geneva Health Forum 2012. (Research project).
 35. Awoyemi OB, Ige OM, Onadeko BO. Prevalence of active pulmonary tuberculosis in human immunodeficiency virus seropositive adult patients in University College Hospital, Ibadan, Nigeria. *Afr J Med Med Sci* 2002;31:329-32.
 36. Salami AK, Katibi IA. Human immunodeficiency virus-associated tuberculosis: Pattern and trend in the University of Ilorin Teaching Hospital. *Afr J Med Med Sci* 2006;35:457-60.
 37. Nwabuko CO, Ejele OA, Chuku A, Nnoli MA, Chukwuonye II. Prevalence of tuberculosis-HIV coinfection and relationship between tuberculosis and CD4/ESR in HIV patients in Niger Delta Region of Nigeria. *J Dent Med Sci* 2012;2:1-4.
 38. Iliyasu Z, Babashani M. Prevalence and predictors of tuberculosis coinfection among HIV-seropositive patients attending the Aminu Kano Teaching Hospital, Northern Nigeria. *J Epidemiol* 2009;19:81-7.
 39. Olaniran O, Hassan-Olajokun RE, Oyovwevotu MA, Agunlejika RA. Prevalence of tuberculosis among HIV/AIDS patients in Obafemi Awolowo University Teaching Hospital Complex OAUTHC, Ile-Ife. *Int J Biol Med Res* 2011;2:874-7.
 40. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. *Am J Respir Crit Care Med* 2005;172:123-7.
 41. Auld AF, Mbofana F, Shiraiishi RW, Alfredo C, Sanchez M, Ellerbrock TV, *et al.* Incidence and determinants of tuberculosis among adults initiating antiretroviral therapy - Mozambique, 2004-2008. *PLoS One* 2013;8:e54665.
 42. Chu R, Mills EJ, Beyene J, Pullenayegum E, Bakanda C, Nachega JB, *et al.* Impact of tuberculosis on mortality among HIV-infected patients receiving antiretroviral therapy in Uganda: A prospective cohort analysis. *AIDS Res Ther* 2013;10:19.
 43. Wondimeneh Y, Muluye D, Belyhun Y. Prevalence of pulmonary tuberculosis and immunological profile of HIV co-infected patients in Northwest Ethiopia. *BMC Res Notes* 2012;5:331.
 44. Gudina EK, Gudissa FG. Prevalence of tuberculosis in HIV in Ethiopia in early HAART era: Retrospective analysis. *Pan Afr Med J* 2013;14:126.
 45. World Health Organization. Consolidated Guideline on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2013.